drugset / Trial / NCT00553735

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

NCT00553735

Phase 4 Terminated 8 enrolled Massachusetts Eye and Ear Infirmary
RandomizedSingle-groupTriple-blindPrevention

Summary

The purpose of this study is to determine whether Restasis is an effective treatment for preventing the occurrence and progression of dry eye syndrome in patients who have recently received a bone marrow transplant and are at risk to graft-versus-host disease.

Timeline

Start
2007-08
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 0.05 % Topical

Indications